Calley Means, advisor to RFK Jr., challenges drugmakers considering pulling investment in the US over Trump's most favored ...

A Delaware jury on Thursday said Regeneron should get more than $400 million in damages in its long-running antitrust case ...

The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...

Bristol Myers Squibb CEO Chris Boerner said America’s role as the global biopharma leader is at a 'pivot point' as the Trump ...

Datavant acquires Aetion in health data merger. Deal doubles life sciences team to 400. CEO Kyle Armbrester says company has ...

AGC Bio partners with Quell for vectors; Thermo Fisher makes Cybin's CYB003; PeptiSystems teams with Asahi Kasei; TriLink & ...

Merck KGaA keeps US tariff surcharge while pausing China fees; cuts sales guidance to €20.9-22.4B amid economic uncertainty.

HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...

GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...

AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...

Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...